Prostate-Specific Membrane Antigen-Targeted Site-Directed Antibody-Conjugated Apoferritin Nanovehicle Favorably Influences In Vivo Side Effects of Doxorubicin

Simple item page
dc.contributor.authorDostálová, Simonacs
dc.contributor.authorPolanská, Hanacs
dc.contributor.authorSvobodová, Markétacs
dc.contributor.authorBalvan, Jancs
dc.contributor.authorKryštofová, Olgacs
dc.contributor.authorHaddad, Yazan Abdulmajeed Eyadhcs
dc.contributor.authorKřížková, Soňacs
dc.contributor.authorMasařík, Michalcs
dc.contributor.authorEckschlager, Tomášcs
dc.contributor.authorStiborová, Mariecs
dc.contributor.authorHeger, Zbyněkcs
dc.contributor.authorAdam, Vojtěchcs
dc.coverage.issue8867cs
dc.coverage.volume8cs
dc.date.accessioned2020-08-04T11:04:14Z
dc.date.available2020-08-04T11:04:14Z
dc.date.issued2018-06-11cs
dc.description.abstractHerein, we describe the in vivo effects of doxorubicin (DOX) encapsulated in ubiquitous protein apoferritin (APO) and its efficiency and safety in anti-tumor treatment. APODOX is both passively (through Enhanced Permeability and Retention effect) and actively targeted to tumors through prostate-specific membrane antigen (PSMA) via mouse antibodies conjugated to the surface of horse spleen APO. To achieve site-directed conjugation of the antibodies, a HWRGWVC heptapeptide linker was used. The prostate cancer-targeted and non-targeted nanocarriers were tested using subcutaneously implanted LNCaP cells in athymic mice models, and compared to free DOX. Prostate cancer-targeted APODOX retained the high potency of DOX in attenuation of tumors (with 55% decrease in tumor volume after 3 weeks of treatment). DOX and non-targeted APODOX treatment caused damage to liver, kidney and heart tissues. In contrast, no elevation in liver or kidney enzymes and negligible changes were revealed by histological assessment in prostate cancer-targeted APODOX-treated mice. Overall, we show that the APO nanocarrier provides an easy encapsulation protocol, reliable targeting, high therapeutic efficiency and very low off-target toxicity, and is thus a promising delivery system for translation into clinical use.en
dc.formattextcs
dc.format.extent1-13cs
dc.format.mimetypeapplication/pdfcs
dc.identifier.citationScientific Reports. 2018, vol. 8, issue 8867, p. 1-13.en
dc.identifier.doi10.1038/s41598-018-26772-zcs
dc.identifier.issn2045-2322cs
dc.identifier.other148531cs
dc.identifier.urihttp://hdl.handle.net/11012/83822
dc.language.isoencs
dc.publisherSpringer Naturecs
dc.relation.ispartofScientific Reportscs
dc.relation.urihttp://link.springer.com/article/10.1038/s41598-018-26772-zcs
dc.rightsCreative Commons Attribution 4.0 Internationalcs
dc.rights.accessopenAccesscs
dc.rights.sherpahttp://www.sherpa.ac.uk/romeo/issn/2045-2322/cs
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/cs
dc.subjectIn vivo effectsen
dc.subjectDoxorubicinen
dc.subjectApoferritinen
dc.subjectProstate-specific membraneen
dc.subjectAnti-tumor treatmenten
dc.titleProstate-Specific Membrane Antigen-Targeted Site-Directed Antibody-Conjugated Apoferritin Nanovehicle Favorably Influences In Vivo Side Effects of Doxorubicinen
dc.type.driverarticleen
dc.type.statusPeer-revieweden
dc.type.versionpublishedVersionen
sync.item.dbidVAV-148531en
sync.item.dbtypeVAVen
sync.item.insts2020.08.04 13:04:14en
sync.item.modts2020.08.04 12:17:41en
thesis.grantorVysoké učení technické v Brně. Středoevropský technologický institut VUT. Chytré nanonástrojecs
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ProstateSpecific Membrane AntigenTargeted SiteDirected AntibodyConjugated Apoferritin Nanovehicle Favorably Influences In Vivo Side Effects of Doxorubicin.pdf
Size:
6.41 MB
Format:
Adobe Portable Document Format
Description:
ProstateSpecific Membrane AntigenTargeted SiteDirected AntibodyConjugated Apoferritin Nanovehicle Favorably Influences In Vivo Side Effects of Doxorubicin.pdf
Download
Collections
Chytré nanonástroje